This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Optimising Patient Care: Hear from your peers

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

This series of bite sized peer-to-peer videos by experienced clinical nurse specialists, specialist registrars and oncologists has been created to share their knowledge and experience of the day-to-day management of patients with mNSCLC treated with KEYTRUDA® (pembrolizumab) plus chemotherapy.

This module is part of a series of modules looking to share HCPs' experiences across a range of topics. In this module we'll start with how patients go into combination treatment and explore the proposed mode of action for KEYTRUDA. We'll then look at the types of immune related adverse events which patients on KEYTRUDA plus chemotherapy may experience and how they may be managed. Finally, we'll hear from a nurse about supporting patients as they complete their treatment and transition off KEYTRUDA.

Licensed indication

This module is CPD certified, offering a certificate upon completion.

You will need to be signed in to MSD Connect to download the certificate.

Register or Login to MSD Connect

Watch at least 80% of the way through each of the videos below, in order to be able to download the certificate.

Watch videos below to progress the module

This module is CPD certified, offering a certificate upon completion.

An introduction to module one of the Peer-to-Peer KEYLearning video series

Length: 00:59 | This video is best viewed in full screen, using the button in the bottom right

Further information

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

The role of PD-L1 testing in selecting patients for immunotherapy plus chemotherapy

Length: 08:46 | This video is best viewed in full screen, using the button in the bottom right

Further information

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Explaining the mode of action of KEYTRUDA (pembrolizumab) plus chemotherapy combination therapy to patients

Length: 08:31 | This video is best viewed in full screen, using the button in the bottom right

Further information

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Using KEYTRUDA (pembrolizumab) plus chemotherapy in patients with pre-existing autoimmune disease

Length: 03:42 | This video is best viewed in full screen, using the button in the bottom right

Further information

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Overview of immune-related adverse events in patients treated with KEYTRUDA plus chemotherapy

Length: 09:53 | This video is best viewed in full screen, using the button in the bottom right

Further information

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Extending guidance for managing chemotherapy-related adverse events to include immune-related adverse events

Length: 07:20 | This video is best viewed in full screen, using the button in the bottom right

Further information

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Distinguishing between an immunotherapy and chemotherapy-related adverse event

Length: 07:28 | This video is best viewed in full screen, using the button in the bottom right

Further information

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Supporting patients through the transition at the end of their KEYTRUDA (pembrolizumab) plus chemotherapy treatment

Length: 06:45 | This video is best viewed in full screen, using the button in the bottom right

Further information

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

A Summary of module one of the Peer-to-Peer KEYLearning video series

Length: 01:04 | This video is best viewed in full screen, using the button in the bottom right

Further information

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Reference

  1. KEYTRUDA Summary of Product Characteristics.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-01803 | Date of Preparation: October 2021